Potential Link Between Proprotein Convertase Subtilisin/Kexin Type 9 and Alzheimer’s Disease
Open Access
- 1 March 2018
- journal article
- Published by Edwiser International in International Journal of Biomedical Investigation
- Vol. 1 (1) , 1-18
Abstract
Alzheimer's disease [AD] is not only the most common neurodegenerative disease but is also currently incurable. Proprotein convertase subtilisin/kexin-9 [PCSK9] is an indirect regulator of plasma low density lipoprotein [LDL] levels controlling LDL receptor expression at the plasma membrane. PCSK9 also appears to regulate the development of glucose intolerance, insulin resistance, abdominal obesity, inflammation, and hypertension, conditions that have been identified as risk factors for AD. PCSK9 levels also depend on age, sex, and ethnic background, factors associated with AD. Herein, we will review indirect evidence that suggests a link between PCSK9 levels and AD.Keywords
This publication has 100 references indexed in Scilit:
- Variation in PCSK9, low LDL cholesterol, and risk of peripheral arterial diseaseAtherosclerosis, 2009
- Alternative splicing of exon 10 in the taugene as a target for treatment of tauopathiesBMC Neuroscience, 2008
- The Role of Amyloid Precursor Protein Processing by BACE1, the β-Secretase, in Alzheimer Disease PathophysiologyJournal of Biological Chemistry, 2008
- Better Memory Functioning Associated With Higher Total and Low-Density Lipoprotein Cholesterol Levels in Very Elderly Subjects Without the Apolipoprotein e4 AlleleThe American Journal of Geriatric Psychiatry, 2008
- PCSK9 is required for the disposal of non‐acetylated intermediates of the nascent membrane protein BACE1EMBO Reports, 2008
- Genetic aspects of Alzheimer diseaseGenetics in Medicine, 2008
- The self-inhibited structure of full-length PCSK9 at 1.9 Å reveals structural homology with resistin within the C-terminal domainProceedings of the National Academy of Sciences, 2007
- Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotypeProceedings of the National Academy of Sciences, 2004
- Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaNature Genetics, 2003
- Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset FamiliesScience, 1993